Asia-Pacific monoclonal antibodies market is estimated to grow at a CAGR of 8.9% during the forecast period. Significant rise in the incidences of cancer and infectious diseases and increasing approvals of biosimilars are primarily encouraging the market growth. The rising number of approvals for monoclonal antibodies biosimilars has been reported in the region owing to the increasing government focus towards improving access to care for patients. For instance, in October 2020, Cadila Pharmaceuticals introduced two similar biologics in the Indian market. This includes Cadalimab, a similar biologic of the auto-immune treatment adalimumab, and NuPTH, a teriparatide similar biologic. Cadila has revealed four new products in India since July 2020.

Request a free sample of our report on Asia-Pacific Monoclonal Antibodies Market: https://www.omrglobal.com/request-sample/asia-pacific-monoclonal-antibodies-market

Adalimumab is a monoclonal antibody therapy for inflammatory diseases which include several types of arthritis, psoriasis, and inflammatory bowel disease (IBD). Adalimumab was the first human monoclonal antibody treatment approved by the US FDA which is sold with the brand name Humira since 2003. A biosimilar of adalimumab is sold as Cadalimab which is available in a form of a pre-filled syringe to facilitate ease of use. This biosimilar has been demonstrated to be effective to treat rheumatoid arthritis, psoriatic arthritis, juvenile idiopathic arthritis, psoriasis, and ankylosing spondylitis. It is available in a 40 mg/0.8 mL injectable dose. The increasing launches of biosimilars are offering hope for patients with cancer, auto-immune diseases, infectious diseases, and others, to receive affordable treatment. This, in turn, is providing an enormous scope for market growth.

A full report of Asia-Pacific Monoclonal Antibodies Market Is available at https://www.omrglobal.com/industry-reports/asia-pacific-monoclonal-antibodies-market

Asia-Pacific Monoclonal Antibodies Market Segmentation

By Source

Murine

Chimeric

Human

Humanized

By Application

Cancer

Infectious Diseases

Auto-Immune Diseases

Inflammatory Diseases

Others

Regional Analysis

China

India

Japan

Rest of Asia-Pacific

Company Profiles

Amgen Inc.

Anhui Anke Biotechnology (Group) Co., Ltd.

Biocon Ltd.

Chugai Pharmaceutical Co., Ltd.

Daiichi Sankyo Company, Ltd.

Dr. Reddy's Laboratories, Inc.

GenorBioPharma Co., Ltd.

Lupin Ltd.

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

Takeda Pharmaceutical Co., Ltd.

For more customized data, request for report customization @ https://www.omrglobal.com/report-customization/asia-pacific-monoclonal-antibodies-market

About Us:

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting, and other research-based services.

For More Information, Visit https://www.omrglobal.com/

Media Contact:

Company Name: Orion Market Research

Contact Person: Mr. Anurag Tiwari

Email: [email protected]

Contact no: +91 780-304-0404